Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual... by Vincenzo Nasca, Francesca Bergamo, Luisa Foltran, Lorenzo Antonuzzo, Katia Bencardino, Emanuela Dell’Aquila, Salvatore Corallo, Andrea Spallanzani, Oronzo Brunetti, Daniele Spada, Stefano Tamberi, Chiara Alessandra Cella, Antonio Avallone, Lorenzo Fornaro, Samantha Di Donato, Antonia Strippoli, Alberto Puccini, Emiliano Tamburini, Federica Palermo, Federica Morano, Filippo Pietrantonio, Alessandra Raimondi

Get full text